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The Glycation Gap (GGap) and the similar Hemoglobin Glycation Index (HGI) define 
consistent differences between glycated hemoglobin and actual glycemia derived from 
fructosamine or mean blood glucose respectively. Such a disparity may be found in a 
substantial proportion of people with diabetes, being  > than 1 unit of glycated HbA1c% or 7.2 
mmol/mol in almost 40% of estimations.  In this review we define these indices, explain how 
they can be calculated and that they are not spurious, being consistent in individuals over 
time.  
We evaluate the evidence that GGap and HGI are associated with variation in risk of 
complications and mortality and demonstrate the potential for clinical error in the 
unquestioning use of HbA1c. We explore the underlying etiology of the variation of HbA1c 
from mean glucose in blood plasma including the potential role of enzymatic deglycation of 
hemoglobin by fructosamine-3-kinase. We conclude that measurement of GGap and HGI are 
important to diabetes clinicians and their patients in individualization of therapy and the 
avoidance of harm arising from consequent inappropriate assessment of glycaemia and use of 
therapies.  
 
I. INTRODUCTION  
HbA1c has become the sine qua non of diagnosis and of clinical study outcome measures with 
few diabetes professionals questioning its apparent validity (1). Nevertheless a historical 
perspective shows that, in fact, many doubts have been aired over the last 30 years about such 
an unquestioning assumption (as recently underlined by Cohen and colleagues (2)). Whilst for 
the majority of patients with (or suspected of having) diabetes mellitus the use of HbA1c 
provides a tool that yields helpful guidance in diagnosis and treatment, there is an increasing 




is appropriate (3). In short, for these patients the blunt use of HbA1c to guide treatment and 
diagnosis may lead to significant clinical errors. It is therefore important for those involved in 
the care of patients to understand the impact of the “Glycation Gap” (GGap) and its sister the 
“Hemoglobin Glycation Index” (HGI) on the validity of HbA1c measurements (4–6). 
 
II. Non-enzymatic glycation of blood proteins and use in estimating average 
glycemia 
Hyperglycaemia of diabetes is associated with increased glycation of free amino-groups in 
proteins. Protein glycation is a key factor leading to vascular complications and furthermore, 
when occurring in erythrocyte proteins, provides the widely used index of average glycaemia, 
HbA1c or glycohaemoglobin (GHb) (7). Glycation occurs as a result of the well-known 
reaction of carbohydrate moieties with amino groups of proteins known since 1910 as the 
Maillard, or more specifically when involving glucose, as the Schiff reaction. The aldimine 
product of the Schiff reaction undergoes slow but reversible rearrangement to the Amadori 
ketoamine product. The ketoamine is then slowly converted to advanced glycation end-
products which comprise a wide range of chemical moieties which contribute to the 
development of complications of diabetes (for review see Zhang et al., 2009 (8)) 
 
Accurate quantification of glycaemia with reliable and practicable tests was historically a 
challenge. Before the development of accurate point-of-care devices blood glucose 
measurement and monitoring depended on inaccurate clinic or home based “stick” testing of 
blood glucose or else necessarily infrequent laboratory measurements. 
 
As early as 1964, an unusual abnormal hemoglobin, HbA1c (“blocked” at the N-terminus of 




a “glycosylated” variant which was elevated by approximately 2 fold in patients with diabetes 
along with other variants HbA1a and HbA1b compared to those without (10,11). HbA1c was 
later shown to be the majority sub-component of total glycated hemoglobin, resulting from 
non-enzymatic glycation at the N-terminal valine of the beta chain of hemoglobin A; other 
glycations by glycolytic intermediates fructose-1,6-bisphosphate and glucose-6-phosphate 
produce variants such as HbA1a and Hb1b and glycation at amino groups of intra-chain lysines 
also occur but do not affect the chromatographic mobility of Hb. Originally referred to as 
glycosylated hemoglobin, the concept of glycation, a non-enzymatic reaction between glucose 
and free amino-groups on proteins, was developed to distinguish this process from the post-
translational glycosylation of proteins and the use of the name “glycated hemoglobin” was 
proposed in 1983 (IUPAC) (12). As described above, glycation results from initial reversible 
reactions - the Schiff/Maillard reaction producing an aldimine followed by a further Amadori 
rearrangement to a more stable glycated ketoamine (proteins thus containing fructosyl-lysine 
or fructosyl-(N-terminal) amino acids). Subsequently clinical studies confirmed that HbA1c 
could be used as a measure of glycaemic control (13), its assays are now standardised (14), 
and currently glycated HbA1c is considered the gold standard measure of glycaemia over the 
preceding 3 months, closely associated with key microvascular complications in diabetes, 
proven risk reduction in complications with improvement in HbA1c towards the normal non-
diabetic range and more recently implemented internationally in the diagnosis of diabetes 
mellitus (1, 15,16).  
 
However, a similar non-enzymatic glycation process occurs extracellularly with plasma 
proteins, predominantly albumin. Fructosamine is a marker derived from all ketoamine 
products occurring as a result of glycation of serum proteins and is measured by the nitroblue 




glycaemic control as HbA1c, representing glycaemia over a shorter duration (because of the 
shorter half-life of serum proteins) than reflected by HbA1c and associated with microvascular 
complications in diabetes similar to HbA1c (17,18). Fructosamine as a measure of glycaemic 
control has been validated against glycated HbA1c and blood glucose (19,20). Newer assays 
for fructosamine estimation, are based on more specific enzymatic ketoamine oxidation 
compared to NBT reduction (which is subject to interference by endogenous reducing 
substances etc.), although the two assays correlate closely (21).  Direct assay of glycated 
albumin, reflecting glycaemic control over weeks, has been used in some countries, has 
gained importance in glycaemic monitoring, and is associated with microvascular 
complications in diabetes (17, 22) 
 
 
III. Limitations to the clinical utility of HbA1c – consequences of GGap and HGI 
Current strategies in the management of glycemia in diabetes rely heavily on HbA1c. Despite 
standardization of assays, discrepancy between HbA1c and other assessments of glycemia is 
well reported and may affect accurate interpretation of glycemic control and its management 
(3–6, 23, 24). A variety of erythrocytic factors that impacts on red cell life span or turnover 
and glucose gradient across the red cell membrane, are known to affect HbA1c independently 
of glycemia (25,26). Recent changes in glycemic control are possibly over-represented in 
HbA1c i.e. HbA1c does not reflect blood glucose levels equally over the previous 120 days.  
HbA1c represents the net effect of several mechanisms, which may shift its direct glycation 
relationship with overall levels of glycemia. Various studies have calculated the deviation of 
HbA1c co-utilising either fructosamine or blood glucose data referred to as the “Glycation 
Gap” (GGap, deviation of glycated HbA1c from serum Fructosamine) or the Hemoglobin 




mean blood glucose (MBG) estimations) (4–6, 27-29).  HbA1c could systematically deviate 
from glycemia as a result of elements that influence glycation within the red blood cells such 
that the HbA1c might be lower (a negative GGap or low HGI implies a lower net rate of 
glycation) or higher (positive GGap or higher HGI, implying a higher rate of net 
glycation) than might be expected. 
 
IV. Definition and calculation of GGap and HGI 
Cohen et al. calculated the GGap as the difference between measured HbA1c and the HbA1c 
predicted from Fructosamine based on the population regression of HbA1c on Fructosamine 
(5). Hempe et al. calculated the HGI as the difference between the measured HbA1c and the 
predicted HbA1c derived from date-matched mean blood glucose estimations (MBG) by 
regression (6). Similar methodologies were used by others whereby the GGap was calculated 
based on the regression of HbA1c (y) versus Fructosamine (x)  and HGI was calculated based 
on regression of HbA1c (y) vs. MBG (x) (27-29). Statistically, the calculated GGap (or HGI) 
would thus be a linear function of HbA1c and fructosamine (or MBG); GGap or HGI thus 
calculated would be significantly correlated with HbA1c and hence it would be difficult to 
dissect the association with complications independent of HbA1c. Furthermore the 
fructosamine-derived HbA1c in GGap, or MBG-derived HbA1c in HGI, would not be 
independent of HbA1c – hence it would be statistically spurious to include HbA1c in an 
analysis along with GGap or HGI (30).   
 
We, in a previous study to assess the clinical impact of variability in HbA1c, calculated the 
predicted HbA1c from fructosamine by initially converting the fructosamine value into its 
standard normal deviate (SND) and then the fructosamine SND was converted to HbA1c 





SND[f] = (fructosamine – mean fructosamine)/ SD fructosamine 
F HbA1c = (SND[f]  SD HbA1c) + mean HbA1c 
 
The glycation gap was thus calculated as the difference between the true HbA1c and the 
fructosamine derived standardised predicted FHbA1c (GGap = HbA1c – FHbA1c). In this 
methodology the FHbA1c is not derived from HbA1c by correlation / regression methods (3,4). 
The normalized standard deviate re-allocation of fructosamine levels yields fructosamine 
based HbA1c equivalent results with the same distribution, mean and standard deviation as 
HbA1c without altering the rank position of fructosamine derived values.  
 
Clinically, the analysis used in our published studies (3,4) can be used to obtain a simpler 
estimate of the GGap: Simultaneous HbA1c and fructosamine estimations can be utilised to 
calculate the predicted HbA1c from fructosamine [FHbA1c = (((Fructosamine - 308/77)  1.7) 
+ 8.3] and the GGap (DCCT HbA1c unit) is then calculated as the difference between HbA1c 
(DCCT) and FHbA1c 
 
Recently others have used glycated albumin rather than fructosamine to estimate the GGap 
although this has not been validated against the established method described above (31). 
Although fasting blood glucose estimations are correlated well with mean glucose it is with a 
wide variance, and methodologies using 6 or 8-point glucose profiles provide better 
representation of mean glucose, and hence a relatively better metric to be utilized in the HGI 
calculation. Availability of continuous glucose monitoring (CGM) with high density of data 
and better reflection of postprandial peaks could help in mean glucose calculations (and most 




individual patients (2)), however this has not yet been explored in HGI calculation; it may be 
noted nevertheless that mean glucose profiles were similar comparing CGM and 8-point 
blood glucose testing (32).  
 
Despite the availability of such new technologies in some arenas it should be recognized that 
CGM is yet to be widely available in a large proportion of clinical situations and that HbA1c 
and/or GA/fructosamine will continue to be the major methods of monitoring glycemia 
worldwide for many years. Crucially, the calculation of GGap and HGI will continue to 
provide important information in relation to individual risk of diabetic complications as 
discussed in section VIII below. 
 
V. Alternative explanations of the GGap/HGI 
The use of HbA1c depends on the assumption that erythrocyte (intracellular) glucose 
concentrations are an accurate reflection of plasma (extracellular) glucose on the basis that 
erythrocytes express the constitutive glucose transporter GLUT1, however this assumption 
may be incorrect for a number of reasons and furthermore the utility of glycated hemoglobin 
as an indicator of average glucose over the half-life of hemoglobin of 3 months assumes that 
there is no further change in the glycated product and indeed that the half-life (or life span 
determined as the “mean RBC age”, MRBC) of erythrocytes is consistent between individuals 
which it demonstrably is not (2); Malka et al. recently suggested a mathematical model for 
calculating individual MRBC, which measure they propose as the explanation for all individual 
non-glycemic HbA1c variability and as a correction to be used in patient-personalized 
assessment of HbA1c results (33). GGap and HGI could potentially be explained by genetic 




glycemic factors including alterations in GLUT1 expression or activity or intracellular 
enzymatic deglycation pathways, which are discussed below (sections VIII and IX). 
 
VI. Consistency of GGap and HGI 
It has been hypothesised that GGap and HGI represent a spurious statistical phenomenon (30; 
34) arising from regression analysis used in some methodologies and on this basis Lachin et 
al. (34) suggest that HGI is not completely glycemia-independent and hence not an 
independent predictor of complications (see section VII). Our method of calculating GGap 
using the standardized normal deviate (section IV) avoids this problem (3,4), furthermore the 
consistency of GGap and HGI mitigates against this criticism;  hence GGap and HGI have 
both been shown to be consistent in individuals over time, indicating a constant variation in 
intracellular glycation compared to extracellular glycation or glycaemia as measured by 
serum Fructosamine or MBG (4–6). In a retrospective study on 2,263 individuals with 
diabetes, by using multiple simultaneously measured HbA1c and fructosamine in the same 
individuals over an extended time period, we confirmed the GGap can be of substantial 
magnitude, that there is no significant within-subject variability in the GGap and that the 
direction of the GGap is consistent despite significant changes in HbA1c and fructosamine 
over the time period (4) (these findings are updated, extended and explored in more detail 
below section X and Figs 1-3). Others have demonstrated such reproducibility of GGap: 
Cohen et al. reported the reproducibility of the GGap in 65-paired HbA1c-fructosamine 
estimations separated by 23 weeks in a population with diabetes (5). In a population not 
known to have diabetes, Yudkin et al. (35) and Gould et al. (36) showed that the discrepancy 
between the HbA1c relative to fasting and 2-hour blood glucose levels in the oral glucose 
tolerance test (OGTT) remained consistent over a 4.4-year period (29,30) . Similarly 




to be consistent over a 2-year study period (6). It was shown that individuals consistently had 
the same direction and magnitude of HGI from repeated measurements of HbA1c and MBG 
over a 2-year period in a clinic population of children and adolescents with type 1 diabetes. 
 
A comparison of GGap and the HGI in 62 patients with type 1 diabetes confirmed that the 
two indices are highly correlated and consistent (37). In a study in monozygotic twins, GGap 
was suggested to be 69% inheritable, indicating the possibility of a genetic basis for the GGap 
(38). 
 
Recent studies examining GGap and HGI in Korean patients with type 2 diabetes, in which 
glycated albumin rather than fructosamine was used in the GGap calculation, have confirmed 
the correlation between these the two indices and also further demonstrated their consistency, 
and interestingly that patients with a high HGI/positive GGap had a higher incidence of 
insulin use, albeit in a small study group (39). Akatsuka et al. suggest that the ratio of 
glycated albumin to HbA1c in IFCC units is an accurate measure of GGap and might be useful 
as a reference for predicting risk of complications in type 1 diabetic children (40). 
 
VII. Association of diabetes complications with GGap and HGI 
GGap/HGI might alter an individual’s risk of vascular complications for any given level of 
long-term glycaemic control by modifying one of the key pathologic processes, namely, 
protein glycation and the formation of advanced glycation end products. Hypothesizing that 
the GGap is a trivial nonsystematic event, unconnected to diabetes outcomes, it would not 
then be expected to be associated with distinct subpopulations of human diabetes or to have 
any sequelae in clinical outcomes. We have reported the direct associations between positive 




consistent with the glycation mechanism for complications (41). Belonging to the consistently 
positive GGap group was significantly associated with worsening retinopathy (odds ratio 
[OR] 1.96 [95% CI 1.31–2.9], P=0.001), increasing urine albumin Creatinine ratio (1.85 
[1.14–3.01], P = 0.012), and the presence of established macrovascular disease (1.91 [1.18–
3.09], P=0.008). Others have reported a similar relationship between the GGap/ HGI and 
retinopathy and nephropathy. Cohen et al. suggested that the GGap increased the risk of more 
advanced nephropathy 2.9-fold (5). Rodrıguez-Segade et al. examined 2,314 patients with 
type 2 diabetes for a mean of 6.5 years, dividing the cohort into tertiles based on the average 
of all individual GGaps, and showed that the mean GGap predicts the progression of 
nephropathy (42). In a study analyzing the data from DCCT, HGI was shown to be a 
significant predictor of retinopathy and nephropathy (43). Furthermore the HGI sub-group 
analysis of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial revealed 
that intensive treatment significantly reduced the primary composite outcome (first 
occurrence of non-fatal myocardial infarction, non-fatal stroke, or death from other 
cardiovascular causes) by 25% in the low HGI subgroup and by 23% in the moderate HGI 
subgroup but not in the high HGI sub-group where the primary outcomes were similar 
between the standard and intensive glycaemia treatment groups (44). In the ACCORD cohort, 
fasting glucose values were used to calculate the predicted HbA1c and the HGI, potentially not 
taking into consideration of the effect of the post-prandial glucose variations that may have 
impacted on the HGI. 
 
We also examined mortality in our cross-sectional, retrospective study and found that the 
adjusted all-cause mortality was higher (2-fold) both in the negative and positive GGap 
groups compared to neutral GGap cohort (41). Cid Alvarez et al. in a prospective cohort study 




demonstrated an association of increased mortality with higher GGap values (diabetes cohort 
HR IC 95%: 1.31 (1.14-1.50), P<0.001; and non-diabetic patients HR IC 95%: 1.30 (1.04-
1.64), P=0.018) (45). HGI subgroup analysis in the cohort from ACCORD trial also suggested 
increased total mortality by 41% (P = 0.02) in the high HGI group but not in low and 
moderate HGI group, in those in the intensive treatment arm (44). 
  
In the cohort of patients with type 2 diabetes studied in the Action in Diabetes and Vascular 
Disease (ADVANCE) Trial, HGI was found to be a strong predictor of microvascular, 
macrovascular complications and mortality irrespective of the treatment allocation (intensive 
vs. standard treatment) but no better than HbA1c. Further it was noted that intensive control 
reduced mortality in the high HGI cohort (high measured HbA1c relative to that predicted 
from MBG) (46). This result was inconsistent with the findings of the ACCORD trial 
however the difference in the treatment regimen in the 2 trials is likely to have contributed to 
the different findings.  
 
Similarly to our findings of the relationship of GGap with mortality (41), in a study of 976 
individuals with diabetes with ischaemic stroke, high and low HGI were linked to poor 
outcome, with a U-shaped association of HGI with prognosis being demonstrated (47).  
Table 1 summarizes the published studies demonstrating the association between GGap/HGI 
and diabetic complications.  
 
VIII. Possible contributions to the GGap / HGI 
Since the GGap or HGI is a measure of the net difference between HbA1c and Fructosamine 





As previously indicated the time frame of glycemic attainment represented by fructosamine is 
shorter than that of HbA1c, the glycation it indicates may be influenced by protein turnover 
rates and protein loss as proteinuria, and these factors may play a part in the GGap. Many 
have shown a good relationship between HbA1c and fructosamine (3-5, 27). Fructosamine is 
known to be well associated with preceding blood glucose levels (19). A concern relating to a 
possibly confounding association of fructosamine levels with proteinuria has been raised, 
however in our study utilising regression analysis of fructosamine with multiple relevant 
clinical and biochemical factors we showed that, overall, they explained no more than 20% of 
the variance in fructosamine, which is to say 80% of fructosamine is not associated with any 
known influencing factor (41), amongst which urine albumin-creatinine ratio had the 
statistically weakest independent association, with an r
2
 of 0.002 thus representing only 0.2% 
of the accountable variance of fructosamine. 
 
A variety of factors independent of prevailing glycemia influence glycated HbA1c. Genetic 
variations could influence HbA1c through non-glycemic pathways and contribute to HbA1c-
glycemia discordance (54).  A previous study has confirmed that glycation gap may be partly 
genetically determined and account for one third of the heritability of HbA1c (38).  
 
Bergenstal et al. demonstrated racial difference in the relationship between HbA1c and 
glycaemia, confirming that HbA1c levels overestimate the mean glucose concentration in 
black persons compared with white persons, suggesting that there may be racial differences in 
the glycation of hemoglobin (55). Such ethnic differences which have a likely genetic 
component have also been demonstrated in a new study by Hivert et al. (56) and the authors 
point out that an association of a genetic variant in G6PD, which is common in black 




importance of the effect of HbS found mainly in African-American populations on HbA1c 
assays is also apparent (58), although this is an effect which laboratories are aware of and 
therefore normally allow for. Factors that impact on red cell survival or those which regulate 
intracellular glucose concentrations - including glucose permeability across the red cell 
membrane, independent of extracellular glucose - have been shown also to contribute to the 
extent of hemoglobin glycation (23-25). The variability in the intracellular glucose relative to 
extracellular glycaemia significantly contributes to variation in HbA1c. Other factors that 
influence non-enzymatic hemoglobin glycation include intracellular pH, 2,3-
diphosphoglycerate concentration and glycolytic enzyme activity (36).   
 
IX. Differential rates of intra-cellular glycation independent of glucose: 
fructosamine-3-kinase as a deglycating enzyme associated with the GGap 
One possible explanation of the GGap that has been mooted is that of an enzyme-mediated 
intracellular deglycation process. We have recently adduced evidence of a potential role of the 
enzyme fructosamine-3-kinase (FN3K) enzyme in the GGap. FN3K has previously been 
shown to phosphorylate aldimine Amadori products of protein glycation at specific amino-
groups in hemoglobin and other proteins, effectively deglycating the protein and restoring the 
free amino-group with the production of deoxyglucosone (59). FN3K is a predominantly 
intracellular enzyme expressed highly in erythrocytes (60). Single nucleotide polymorphisms 
(SNPs) in the FN3K gene have been shown to be associated variously with HbA1c levels and 
circulating soluble receptors for AGE (sRAGE) (61, 62) and genome-wide association studies 
(GWAS) have found the fn3k gene to be one of the top hits for association with HbA1c (63, 





We studied erythrocyte FN3K concentrations and enzyme activity in a sub-set of our diabetes 
patient population, dichotomised for a large positive or negative GGap (65). We showed that 
FN3K protein was significantly higher and, strikingly, that FN3K enzyme activity was 3-fold 
greater at any given FN3K protein level in the erythrocytes of the negative compared with 
positive GGap groups. This was associated with significantly lower advanced glycation end 
product (AGE) levels, lower pro-inflammatory adipokines (Leptin/Adiponectin ratio) and 
much lower pro-thrombotic PAI-1 levels in the negative GGap cohort, thus suggesting a 
possible role of FN3K as a deglycating enzyme in diabetes complications, potentially 
reducing some of the AGE involved in the pathogenesis of diabetes complications (65). 
 
An objection to the potential role of FN3K in the GGap arises from its higher rate of activity 
in respect of fructosyl-lysines generated by glycation of side-chain amino-groups in proteins, 
coupled to its reportedly low activity on N-terminal amino-groups such as that of the N-
terminal valine on Hb beta-chains (66). Thus the specificity of FN3K to N-ε-fructosyl-lysine  
(FruLys) compared with “N-terminal” N-α-fructosyl amino acids reportedly ranges from 100 
times to 10 times lower affinity (67). This argument may be countered by considering the 
long time period over which FN3K may be able to act within the erythrocyte and since a 
lower affinity simply suggests a slower, but not zero-rate reaction (especially if the difference 
is only 10-fold) a significant degree of deglycation at the N-terminal valine may still occur. It 
must also be considered that published affinity values for FruLys comprise the free amino 
acid and the protein-bound or histone-bound FruLys, whereas for N-α–bound Amadori 
products only the free amino acids have been examined (59, 60). Indeed there is preliminary 
evidence of significantly measurable activity on N-α–bound Amadori products such as 




demonstrated such a marked difference in FN3K activity in relation to GGap also supports the 
contention that it has a significant role in the GGap (65). 
 
X. Clinical implications of GGap and HGI 
The disagreement between HbA1c and other measures of glycaemia including fructosamine or 
MBG, as calculated by GGap or HGI respectively, can be substantial in magnitude and is 
consistent over time (3-6, 27). Thus utilising HbA1c, the current gold standard for assessment 
of glycemic control in diabetes, alone could potentially under or overestimate the prevailing 
glycemia, and leading to error in clinical assessment and management. Moreover use of the 
derived estimated average glucose (eAG) is more likely to result in overlooking the 
limitations of the HbA1c measurement from which it is calculated (68). Individuals with a 
high GGap or high HGI, wherein the HbA1c is higher than indicated by the serum 
fructosamine or MBG respectively, may receive an up-titration of their glycaemia treatment 
that may put them at undue risk of hypoglycemia if the GGap/ HGI is not taken into account 
(and several studies confirm that this does happen in practice). On the other hand in the case 
of those with a negative GGap / low HGI, wherein the HbA1c is lower than the prevailing 
glycaemia, clinicians may be falsely reassured by HbA1c, resulting in no appropriate therapy 
intensification to improve glycemia, putting such individuals at risk of diabetes-related 
complications. The HGI subgroup analysis in the ACCORD Trial suggested that the incidence 
of hypoglycemia was progressively higher in the low, moderate, and high HGI subgroups in 
both intensive (14.5, 16.8, and 18.8%, respectively) and standard (3.7, 4.5, and 7.5%, 
respectively) glycemia treatment cohorts (44).  
 
HbA1c arguably still has value as a risk marker in diabetes risk stratification, prediction, 




danger of not questioning its validity in the subset of individuals where there is potential for 
large errors is apparent from the discussion in the preceding paragraph. Setting aside 
considerations of its calculation, its impact on vascular risk and mortality and its possible 
underlying aetiology, the key purpose of this review is to raise awareness of the potential of 
HbA1c inaccuracy for this subset of patients,  reflected in the GGap (and HGI), to result in 
significant error in the assessment of glycemic control. In order to assess the possible scale of 
this error (and thus the probable size of the patient subset) we extended and re-analysed the 
data previously published (3) and we have recently reported the findings of this re-analysis 
(69). These findings are highlighted in Figure 1 which shows our total accrued data on 31,119 
simultaneously measured HbA1c and fructosamine estimations undertaken in our single 
center over 10 years. It is apparent from this figure that there is wide scatter around the line of 
unity which, in absolute terms, was > than 1 unit of glycated HbA1c% or 7.2 mmol/mol in 
40% of estimations.  
 
Figure 2 shows how this scatter results in differences in the categorisation of glycemic 
attainment between HbA1c and fructosamine-derived FHbA1c. Whilst many people with 
diabetes in our center would be accurately categorized for glycemic attainment based on 
HbA1c, a large proportion would be not be. This is demonstrated in Figure 3 which depicts the 
magnitude of the variance in that categorisation, with only 46% showing concordance and 
15% of patients having, in our opinion, a large enough difference to impart certain risk by 
way of error in a clinician’s judgement, with consequent  potential for  inappropriate therapy 
and management.  
 
It may thereby be, as reported by ACCORD (42), that those in lower attained HbA1c brackets 




came to harm. A recent review by Campbell et al. (24) suggests that the GGap is unlikely to 
cause such errors since “in the main initiation and alterations of diabetic therapies are almost 
never made based on an isolated HbA1c, particularly at levels close to the diagnostic 
threshold”, however as we have seen, because of the individually consistent nature of the 
GGap, multiple measurements of HbA1c  are likely to yield similar conclusions and 
furthermore as we have shown in the preceding paragraph common variations as small as 1% 
in HbA1c from mean glycemia-predicted HbA1c can result in significant clinical errors. This is 
further supported by Cohen et al. (2) quoting a recent study by Rhee et al. (70) who found in 
a “VA population that those whose HbA1c is highest relative to blood glucose (ie equivalent 
to a positive GGap) had a 56% higher frequency of ER visits for hypoglycemia than those 
whose HbA1c is either proportionate or lowest for blood glucose (ie a neutral or negative 
GGap)” (non-italicized insertions are ours). 
 
Understanding the association of GGap and HGI with key diabetes-related microvascular 
complications, as suggested in various studies, in a pattern consistent with key 
pathophysiological mechanism namely glycation of proteins, would help to risk-stratify such 
individuals for targeted risk reduction therapies, and also help in future to develop 
pharmacological interventions aimed towards risk reduction.  The observations of 
significantly different outcomes in the different HGI subgroups in the ACCORD trial in 
response to intensive treatment strongly supports the need for more personalized diabetes 
management and suggests that HGI could be used to help individualize treatment goals.  
 
Given the standardization of HbA1c assays, ease of its estimation and practicality of its use in 
treatment modification (based on available evidence for association with complications and 




diagnosis of diabetes. However the magnitude of GGap/HGI means that this reliance may 
have marked impact in a significant minority of cases. HbA1c alone may not always be 
reliable for diagnostic purposes, with studies showing a low sensitivity of HbA1c for 
diagnosis, leading to substantial number of missed diagnoses and to error in classification of 
diabetes status, in the absence of concurrent use of available glucose criteria for diabetes 
diagnosis. Rodriguez-Segade et al., in a study on patients with previously undiagnosed 
diabetes, confirmed that the differences between HbA1C-based and fasting plasma 
glucose/OGTT-based diagnoses are largely due to the influence of the GGap calculated using 
simultaneously measured serum fructosamine (71). As previously mentioned, the increasing 
availability of CGM in some areas has the potential to provide an alternative to HbA1c in 
assessing glycemic control and Beck, Bergenstal and colleagues have suggested the use of a 
factor derived from CGM which they term the Glucose Management Indicator (GMI) (72, 
73). However, as pointed out above (see the end of section IV) CGM is still not available in 
many constituencies and in others is limited (for funding and other reasons) to a small fraction 
of diabetes patients (for example in the UK, where strict NHS guidelines restrict provision to 
patients with type 1 diabetes having poor control ie substantially less than 5% of diabetes 
patients); furthermore, as we describe in the previous paragraph, determination of GGap or 
HGI (unlike GMI) has the additional benefit of providing a prognostic indicator or risk of 
diabetic complications.   
 
XI. CONCLUSIONS 
In summary, GGap/ HGI can be sufficient in magnitude to cause an error in the judgment of 
glycemia attainment. Hence the incorporation of GGap/ HGI during assessment of glycemic 
control would help to ascertain how far HbA1c diverges from alternative estimates of 




therapeutic management. Understanding the consistency of GGap, its association with a 
phenotype in diabetes, microvascular complications, macrovascular disease and possibly 
mortality, and its possible mechanistic association with FN3K enzyme activity will also 
contribute towards directing further research into emerging therapeutic interventions to lessen 
diabetes related complications.  
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Table 1: Studies investigating the association of diabetic complications with the 
glycation gap (GG) and the hemoglobin glycation index (HGI) 
 
Study (Reference no.) Patient population Results  
GGap (GG) and complications 
Cohen et al. 2003 
(5) 
40 patients with type 1 
diabetes of >15 years 
duration 
GG increase by 1% was associated with 2.9 fold greater 
frequency of adverse nephropathy stage (P=0.0014) 
Rodriguez-Segade et al. 
2011 
(42) 
2,314 patients with type 
2 diabetes  
High GG associated with progression of nephropathy in type 
2 diabetes 
HR (high vs. low GG)=2.52(P<0.001) and HR (medium vs. 
low GG)=1.61(P=0.001) 
Nayak et al. 2013 
(41) 
3,182 patients with type 
1 and type 2 diabetes 
Positive GG is associated with retinopathy (OR 1.24 [95% 
CI 1.01–1.52, P=0.039], nephropathy (1.55 [1.23– 1.95, 
P=0.008]) and macrovascular disease (1.91[1.18–3.09])  
GG had a “U”-shaped quadratic relationship with mortality: 
negative G-gap (1.96 [1.50-2.55], P<0.001) and positive G-
gap (2.02 [1.57–2.60], P<0.001) being associated with a 
significantly higher mortality. 
Cosson et al. 2013 
(48) 
925 patients with type 2 
diabetes  
High GG (third tertile of GG) was associated with 
macroproteinuria (1.6 [1.2–2.1]; P < 0.01) independent of 
HbA1c 
Cid Alvarez et al. 2012 
(45) 
1,137 patients admitted 
with Acute Coronary 
syndrome 
GG was associated with a significantly higher risk of all 
cause mortality in both diabetic [HR IC 95%: 1.31 (1.14-
1.50), P=0.000] and non-diabetic patients [HR IC 95%: 1.30 
(1.04-1.64), P=0.018]. 
HGI and complications 
McCarter et al. 2004 
(41) 
1,441 DCCT participants 
with type 1 diabetes 
High HGI group had greater risk of retinopathy (3-fold) and 
nephropathy (6-fold) compared with low HGI group 
Lachin  et al. 2007 
(34) 
1,441 DCCT participants 
with type 1 diabetes  
The effect of the HGI on microvascular complications in 
DCCT cohort is wholly explained by the associated level of 
HbA1c 
Hempe et al. 2015 
(44) 
10,251 patients with type 
2 diabetes (ACCORD 
cohort) 
Total mortality in intensively treated patients was higher in 
high HGI subgroup (HR 1.41 [95% CI 1.10– 1.80]) 
High HGI was associated with a greater risk for 
hypoglycemia in the standard and intensive treatment 
groups. 
van Steen et al. 2018 
(46) 
11,083 patients with type 
2 diabetes (ADVANCE 
trial cohort) 
High HGI is a predictor of micro- and macro vascular 
complications and mortality but no better than HbA1c 
High HGI associated with lower risk for mortality when on 
intensive treatment 




High HGI associated with higher risk for incident Coronary 
artery calcifications independent of HbA1c 




High HGI associated with 2 fold increased risk of hepatic 
steatosis in non-diabetics 
Cheng et al. 2017 
(51) 
423 individuals with type 
2 diabetes (Taiwan) 
HGI correlated with the extent of CHD in individuals with 
Type 2 diabetes 
Marini et al. 2017 
(52) 
2,055 white non-diabetic 
adults age >=18 years 
HGI is a predictor of Carotid intima-media thickness. 
Individuals with high HGI had 2.7-fold increased risk of 
vascular atherosclerosis (OR 2.72 (1.01-7.37)) as compared 
to individuals with low HGI 
Pan et al. 2017 
(47) 
976 diabetic patients 
with ischaemic stroke 
(China) 
Both high and low HGI were linked to poor outcome in 
acute ischaemic stroke [U-shaped association with OR (95% 
CI) for low vs. moderate HGI group = 1.64(1.13-2.38), 
P=0.01; and high vs. moderate HGI = 1.54(1.06-2.24), 
P= 0.02] 




diabetes or diabetes 
Highest HGI tertile was independently associated with 
composite CVD [OR (95% CI): 2.81 (1.59-4.98)], and 
individual CAD [2.30 (1.12-4.73)], stroke [3.40 (1.50-7.73)], 
and PAD [6.37 (1.18-34.33)] after adjustment for other CVD 






Figure 1: Clinical grid showing variation in categorization of actual HbA1c  and 
estimated fructosamine-derived HbA1c in a single diabetes center over 10 years 
The figure shows 31,119 simultaneously measured HbA1c and Fructosamine estimations. 
F_HbA1c is the derived HbA1c estimated from Fructosamine. The grid shows the levels at 
which HbA1c and F_HbA1c can be arbitrarily categorised as Excellent (≤ 7% (53.0 
mmol/mol), E), Good (7-8% (53.1-63.9 mmol/mol), G), Acceptable (8-9% (64.0-74.9 
mmol/mol), A), Poor (9-10% (75.0-85.8 mmol/mol), P) or Very  Poor (>10% (85.8 
mmol/mol), VP). Glycated hemoglobin levels are depicted in DCCT units for simplicity. All 
values are shown with the degree of scatter around the line of unity whilst horizontal and 
vertical lines represent the defined categories.  
 
Figure 2:  Differences in clinical categorization using actual HbA1c and estimated 
fructosamine-derived HbA1c  
The figure compares the categories of HbA1c  and F_HbA1c  based on the data depicted in 
figure 1. The glycemic control categories on the X-axis (E, excellent; G, good; A, acceptable; 
P, poor; VP, very poor) are those defined using actual HbA1c and the colors show the 
categories that would be derived for the same measurements if based on fructosamine-derived 






Figure 3: Magnitude of variation between glycemic control categories arising from the 
glycation gap 
The figure shows the magnitude of the variance between the categories defined in figure 2. 
This sums all variations which are in agreement, those which are 1 block different, or those 
which are 2 blocks or more different. Less than half (46%) of the paired measurements give 
categorization results which agree when comparing HbA1c and F_HbA1c. 54% disagree by at 
least 1 block and of these 15% disagree by 2 blocks of category or more potentially leading to 
serious clinical misjudgements. 
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